SRF231

American Association for Cancer Research Annual Meeting, June 2020

American Association for Cancer Research Annual Meeting, June 2020

Publication: The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a

Journal for ImmunoTherapy of Cancer, April 2020

Poster:  SRF231, a fully human, high affinity anti-CD47 antibody, exerts potent preclinical antitumor activity through engagement of the FcR, CD32a

Society for Immunotherapy of Cancer Annual Meeting, November 2019

Poster: The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax 

American Society of Hematology Annual Meeting, December 2018

Poster: CD47 Monoclonal Antibody SRF231 is a Potent Inducer of Macrophage-Mediated Tumor Cell Phagocytosis and Reduces Tumor Burden in Murine Models of Hematologic Malignancies

American Society of Hematology Annual Meeting, December 2016

Poster: CD47 mAb SRF231 is a Potent Inducer of Macrophage-mediated Tumor Cell Phagocytosis and has Anti-tumor Activity in Preclinical Models 

Society for Immunotherapy of Cancer Annual Meeting, November 2016